Findings from a 12-week phase 2b study show significant improvement in the signs and symptoms of atopic dermatitis with once-daily treatment of an oral Janus kinase 1 selective inhibitor, abrocitinib 100 mg or 200 mg.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.
